How do health economists value personalised medicine in oncology?

Maarten IJzerman1

1University of Twente, Enschede, The Netherlands

Abstract

Several clinical institutes and collaborative networks have implemented whole genome sequencing. Clinical and basic scientists expect gennome sequencing may change current thinking in healthcare and management of patients, as it allows careful assessment of the molecular basis for targeted treatment. Also, developments in nanomedicine providing high-sensitive detection technologies such as technologies for detection of hypermethylated DNA, cell-free DNA in body fluids, or circulating tumor cells in blood. These markers may have added value for public health screening and for early detection of malignancies.

This presentation introduces the health economic considerations relevant for personalised medicine in general, and more specifically in relation to the added value of genome sequencing.